Century Therapeutics (IPSC) shares were up more than 8% in recent Tuesday trading after the company reported Q3 results that beat market expectations.
The firm posted a Q3 net loss of $0.37 per diluted share, narrowing from $0.55 loss a year ago. Analysts polled by Capital IQ expected $0.45 loss per share.
Revenue for the quarter ended Sept. 30 was $791,000, compared with $148,000 a year earlier. Analysts polled by Capital IQ expected $550,000.
The company said it expects its funds will support operations into the H2 of 2026.
Price: 1.37, Change: +0.11, Percent Change: +8.33